Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing, and commercializing next-generation medicines that treat immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a small molecule RASP (Reactive Aldehyde Species) sequestering agent in Phase 2b clinical development for the treatment of dry eye disease, and Phase 3 clinical development for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. Aldeyra is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal inflammation, metabolic disease, and cancer.
Dry Eye Disease
Dry eye disease is a common and chronic inflammatory disease estimated to affect approximately 20 million people in the United States, and is characterized by insufficient moisture and lubrication in the anterior surface of the eye, leading to dryness, inflammation, pain, discomfort, irritation, and, in severe cases, decreased vision. Among physicians and patients, existing therapy for dry eye disease is generally regarded as inadequate. In patients with dry eye disease, pro-inflammatory aldehyde mediators may contribute to ocular inflammation.
Allergic Conjunctivitis is a common allergic disease that affects more than 20% of the population worldwide. The disease is thought to be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation of the conjunctiva (a membrane covering the front part of the eye), resulting in ocular itching and excessive tear production.
Noninfectious Anterior Uveitis
Noninfectious Anterior Uveitis is a rare but severe and potentially blinding inflammatory disease characterized in part by high aldehyde levels that may cause increased numbers of inflammatory cells in the front of the eye, leading to pain, redness, loss of vision, and other ocular symptoms.